Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its hum… Read more
Avecho Biotechnology Limited (AVEFF) - Net Assets
Latest net assets as of June 2025: $825.16K USD
Based on the latest financial reports, Avecho Biotechnology Limited (AVEFF) has net assets worth $825.16K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.19 Million) and total liabilities ($6.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $825.16K |
| % of Total Assets | 11.47% |
| Annual Growth Rate | -3.67% |
| 5-Year Change | 23.18% |
| 10-Year Change | -88.7% |
| Growth Volatility | 100.77 |
Avecho Biotechnology Limited - Net Assets Trend (1993–2024)
This chart illustrates how Avecho Biotechnology Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Avecho Biotechnology Limited (1993–2024)
The table below shows the annual net assets of Avecho Biotechnology Limited from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.27 Million | -48.73% |
| 2023-12-31 | $6.38 Million | +163.01% |
| 2022-12-31 | $2.42 Million | -46.55% |
| 2021-12-31 | $4.54 Million | +70.91% |
| 2020-12-31 | $2.65 Million | -44.22% |
| 2019-12-31 | $4.76 Million | +22.03% |
| 2018-12-31 | $3.90 Million | -39.10% |
| 2017-12-31 | $6.40 Million | -45.02% |
| 2016-12-31 | $11.65 Million | -59.74% |
| 2015-12-31 | $28.93 Million | -41.00% |
| 2014-12-31 | $49.03 Million | +20.25% |
| 2013-12-31 | $40.77 Million | -34.88% |
| 2012-12-31 | $62.61 Million | -14.17% |
| 2011-12-31 | $72.95 Million | +87.01% |
| 2010-12-31 | $39.01 Million | -21.97% |
| 2009-12-31 | $49.99 Million | -3.03% |
| 2008-12-31 | $51.55 Million | -61.46% |
| 2007-12-31 | $133.76 Million | -1.26% |
| 2006-12-31 | $135.47 Million | +2.53% |
| 2005-12-31 | $132.14 Million | +16.71% |
| 2004-12-31 | $113.22 Million | +285.33% |
| 2003-12-31 | $29.38 Million | +98.42% |
| 2002-12-31 | $14.81 Million | -19.26% |
| 2001-12-31 | $18.34 Million | -11.29% |
| 2000-12-31 | $20.67 Million | +311.51% |
| 1999-12-31 | $5.02 Million | +216.52% |
| 1998-12-31 | $1.59 Million | -70.87% |
| 1997-12-31 | $5.45 Million | -79.95% |
| 1996-12-31 | $27.18 Million | -5.98% |
| 1995-12-31 | $28.90 Million | +167.30% |
| 1994-12-31 | $10.81 Million | +3.81% |
| 1993-12-31 | $10.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avecho Biotechnology Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64857.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $244.61 Million | 7480.89% |
| Other Comprehensive Income | $28.06 Million | 858.05% |
| Total Equity | $3.27 Million | 100.00% |
Avecho Biotechnology Limited Competitors by Market Cap
The table below lists competitors of Avecho Biotechnology Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zena Mining Corp
V:ZCC-H
|
$3.10 Million |
|
Transatlantic Mining Corp
PINK:TRRGF
|
$3.11 Million |
|
Gateway Real Estate AG
XETRA:GTY
|
$3.11 Million |
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
$3.11 Million |
|
IT Tech Packaging Inc
NYSE MKT:ITP
|
$3.10 Million |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
$3.10 Million |
|
AlphaTON Capital Corp.
NASDAQ:ATON
|
$3.10 Million |
|
Investsmart Group Ltd
AU:INV
|
$3.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avecho Biotechnology Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,377,770 to 3,269,738, a change of -3,108,032 (-48.7%).
- Net loss of 3,122,000 reduced equity.
- Other comprehensive income decreased equity by 1,156,671.
- Other factors increased equity by 1,170,639.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.12 Million | -95.48% |
| Other Comprehensive Income | $-1.16 Million | -35.38% |
| Other Changes | $1.17 Million | +35.8% |
| Total Change | $- | -48.73% |
Book Value vs Market Value Analysis
This analysis compares Avecho Biotechnology Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | $0.40 | $0.00 | x |
| 1994-12-31 | $0.39 | $0.00 | x |
| 1995-12-31 | $0.72 | $0.00 | x |
| 1996-12-31 | $0.84 | $0.00 | x |
| 1997-12-31 | $0.16 | $0.00 | x |
| 1998-12-31 | $0.05 | $0.00 | x |
| 1999-12-31 | $0.10 | $0.00 | x |
| 2000-12-31 | $0.25 | $0.00 | x |
| 2001-12-31 | $0.12 | $0.00 | x |
| 2002-12-31 | $0.10 | $0.00 | x |
| 2003-12-31 | $0.19 | $0.00 | x |
| 2004-12-31 | $0.63 | $0.00 | x |
| 2005-12-31 | $0.26 | $0.00 | x |
| 2006-12-31 | $0.24 | $0.00 | x |
| 2007-12-31 | $0.22 | $0.00 | x |
| 2008-12-31 | $0.08 | $0.00 | x |
| 2009-12-31 | $0.07 | $0.00 | x |
| 2010-12-31 | $0.05 | $0.00 | x |
| 2011-12-31 | $0.09 | $0.00 | x |
| 2012-12-31 | $0.06 | $0.00 | x |
| 2013-12-31 | $0.04 | $0.00 | x |
| 2014-12-31 | $0.04 | $0.00 | x |
| 2015-12-31 | $0.02 | $0.00 | x |
| 2016-12-31 | $0.01 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avecho Biotechnology Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -241.27%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.53x
- Recent ROE (-95.48%) is below the historical average (-56.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 7.83% | 0.00% | 0.00x | 1.14x | $-225.60K |
| 1994 | -3.15% | 0.00% | 0.00x | 1.04x | $-1.42 Million |
| 1995 | 60.97% | 0.00% | 0.00x | 1.19x | $14.73 Million |
| 1996 | -11.39% | 0.00% | 0.00x | 1.21x | $-5.81 Million |
| 1997 | -398.12% | 0.00% | 0.00x | 1.01x | $-22.24 Million |
| 1998 | -243.28% | 0.00% | 0.00x | 1.02x | $-4.02 Million |
| 1999 | 10.02% | 0.00% | 0.00x | 1.01x | $1.16K |
| 2000 | -5.68% | 0.00% | 0.00x | 1.01x | $-3.24 Million |
| 2001 | -29.25% | 0.00% | 0.00x | 1.00x | $-7.20 Million |
| 2002 | -29.37% | -3128.46% | 0.01x | 1.00x | $-5.83 Million |
| 2003 | -9.06% | -1108.23% | 0.01x | 1.00x | $-5.60 Million |
| 2004 | -2.78% | 0.00% | 0.00x | 1.01x | $-14.47 Million |
| 2005 | -5.54% | -3979.89% | 0.00x | 1.29x | $-20.54 Million |
| 2006 | -4.52% | -444.16% | 0.01x | 1.28x | $-19.67 Million |
| 2007 | -6.61% | -557.63% | 0.01x | 1.28x | $-22.22 Million |
| 2008 | -176.92% | -3636.60% | 0.04x | 1.34x | $-96.36 Million |
| 2009 | -17.01% | -1268.81% | 0.01x | 1.35x | $-13.50 Million |
| 2010 | -28.91% | -241.95% | 0.09x | 1.38x | $-15.18 Million |
| 2011 | 1.52% | 43.96% | 0.03x | 1.05x | $-6.19 Million |
| 2012 | -17.66% | -860.98% | 0.02x | 1.02x | $-17.32 Million |
| 2013 | -31.08% | -921.00% | 0.03x | 1.05x | $-16.75 Million |
| 2014 | -18.22% | -435.22% | 0.04x | 1.04x | $-13.84 Million |
| 2015 | -69.55% | -918.72% | 0.07x | 1.06x | $-23.01 Million |
| 2016 | -148.66% | -1090.30% | 0.12x | 1.15x | $-18.48 Million |
| 2017 | -133.45% | -743.04% | 0.14x | 1.29x | $-9.19 Million |
| 2018 | -102.34% | -318.77% | 0.26x | 1.23x | $-4.38 Million |
| 2019 | 17.86% | 20.06% | 0.80x | 1.12x | $374.06K |
| 2020 | -99.27% | -685.08% | 0.11x | 1.26x | $-2.90 Million |
| 2021 | -75.30% | -430.44% | 0.15x | 1.16x | $-3.87 Million |
| 2022 | -96.58% | -194.20% | 0.36x | 1.38x | $-2.58 Million |
| 2023 | -53.89% | -725.79% | 0.06x | 1.15x | $-4.07 Million |
| 2024 | -95.48% | -241.27% | 0.26x | 1.53x | $-3.45 Million |
Industry Comparison
This section compares Avecho Biotechnology Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avecho Biotechnology Limited (AVEFF) | $825.16K | 7.83% | 7.72x | $3.10 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |